author-photo

Edward B. Garon

9

Papers

18

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC (vol 14, pg 793, 2019)

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Are lung adenocarcinoma mutations shaping the immune microenvironment

2018 Translational cancer research
- Philippe Rochigneux
- Edward B. Garon
Show All
- Source
- Cite
- Save
Citations (1)
MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)